Methylenetetrahydrofolate reductase polymorphisms in methotrexate treatment of rheumatoid arthritis patients. Review of the literature and personal experience

Methotrexate is still a mainstay of rheumatoid arthritis treatment, but a significant variability in drug response is observed among patients. It has been proposed that C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase (MTHFR), an enzyme involved in the folate pathway, could be r...

Full description

Saved in:
Bibliographic Details
Published in:Reumatismo 2009-06, Vol.61 (2), p.98
Main Authors: Taraborelli, M, Andreoli, L, Archetti, S, Ferrari, M, Cattaneo, R, Tincani, A
Format: Article
Language:eng ; ita
Subjects:
Rheumatoid arthritis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 2
container_start_page 98
container_title Reumatismo
container_volume 61
creator Taraborelli, M
Andreoli, L
Archetti, S
Ferrari, M
Cattaneo, R
Tincani, A
description Methotrexate is still a mainstay of rheumatoid arthritis treatment, but a significant variability in drug response is observed among patients. It has been proposed that C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase (MTHFR), an enzyme involved in the folate pathway, could be related to its efficacy and toxicity. Many studies have investigated the predictive value of such polymorphisms for Methotrexate outcome, though with discordant results. Our experience on 79 patients did not find any significant association between genotype and drug response and the review of the literature did not provide sufficient evidences to support the use of MTHFR genetic screening in clinical practice.
doi_str_mv 10.4081/reumatismo.2009.98
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2440598540</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2440598540</sourcerecordid><originalsourceid>FETCH-proquest_journals_24405985403</originalsourceid><addsrcrecordid>eNqNjstKxEAQRRtRMD5-wFWB68ROpiePtShu3Ij7oZlU6B46qVhd0cnP-K32iB_g6l6oc6ir1F2pC6Pb8oFxGa34OFJRad0VXXumsqoyOq_qdnOuMq1NmzfGdJfqKsaD1nVdNk2mvl9R3BpwQkFh69aeaaBgBYGxX_ZiI8JMYR2JZ5ceRPATjEkiYTyeuJRWRpwEaAB2v0vI92BZHPs0CuY0Ld1jAW_46fHrBIpDCF6QrSyMYKceZuRIkw2Ax1STsccbdTHYEPH2L6_V_fPT--NLPjN9LBhld6CFkxN3lTF627Vbozf_o34A1TVn2A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2440598540</pqid></control><display><type>article</type><title>Methylenetetrahydrofolate reductase polymorphisms in methotrexate treatment of rheumatoid arthritis patients. Review of the literature and personal experience</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Taraborelli, M ; Andreoli, L ; Archetti, S ; Ferrari, M ; Cattaneo, R ; Tincani, A</creator><creatorcontrib>Taraborelli, M ; Andreoli, L ; Archetti, S ; Ferrari, M ; Cattaneo, R ; Tincani, A</creatorcontrib><description>Methotrexate is still a mainstay of rheumatoid arthritis treatment, but a significant variability in drug response is observed among patients. It has been proposed that C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase (MTHFR), an enzyme involved in the folate pathway, could be related to its efficacy and toxicity. Many studies have investigated the predictive value of such polymorphisms for Methotrexate outcome, though with discordant results. Our experience on 79 patients did not find any significant association between genotype and drug response and the review of the literature did not provide sufficient evidences to support the use of MTHFR genetic screening in clinical practice.</description><identifier>ISSN: 0048-7449</identifier><identifier>EISSN: 2240-2683</identifier><identifier>DOI: 10.4081/reumatismo.2009.98</identifier><language>eng ; ita</language><publisher>Pavia: PAGEPress Publications</publisher><subject>Rheumatoid arthritis</subject><ispartof>Reumatismo, 2009-06, Vol.61 (2), p.98</ispartof><rights>2009. This work is published under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2440598540?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,25731,27901,27902,36989,44566</link.rule.ids></links><search><creatorcontrib>Taraborelli, M</creatorcontrib><creatorcontrib>Andreoli, L</creatorcontrib><creatorcontrib>Archetti, S</creatorcontrib><creatorcontrib>Ferrari, M</creatorcontrib><creatorcontrib>Cattaneo, R</creatorcontrib><creatorcontrib>Tincani, A</creatorcontrib><title>Methylenetetrahydrofolate reductase polymorphisms in methotrexate treatment of rheumatoid arthritis patients. Review of the literature and personal experience</title><title>Reumatismo</title><description>Methotrexate is still a mainstay of rheumatoid arthritis treatment, but a significant variability in drug response is observed among patients. It has been proposed that C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase (MTHFR), an enzyme involved in the folate pathway, could be related to its efficacy and toxicity. Many studies have investigated the predictive value of such polymorphisms for Methotrexate outcome, though with discordant results. Our experience on 79 patients did not find any significant association between genotype and drug response and the review of the literature did not provide sufficient evidences to support the use of MTHFR genetic screening in clinical practice.</description><subject>Rheumatoid arthritis</subject><issn>0048-7449</issn><issn>2240-2683</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqNjstKxEAQRRtRMD5-wFWB68ROpiePtShu3Ij7oZlU6B46qVhd0cnP-K32iB_g6l6oc6ir1F2pC6Pb8oFxGa34OFJRad0VXXumsqoyOq_qdnOuMq1NmzfGdJfqKsaD1nVdNk2mvl9R3BpwQkFh69aeaaBgBYGxX_ZiI8JMYR2JZ5ceRPATjEkiYTyeuJRWRpwEaAB2v0vI92BZHPs0CuY0Ld1jAW_46fHrBIpDCF6QrSyMYKceZuRIkw2Ax1STsccbdTHYEPH2L6_V_fPT--NLPjN9LBhld6CFkxN3lTF627Vbozf_o34A1TVn2A</recordid><startdate>20090601</startdate><enddate>20090601</enddate><creator>Taraborelli, M</creator><creator>Andreoli, L</creator><creator>Archetti, S</creator><creator>Ferrari, M</creator><creator>Cattaneo, R</creator><creator>Tincani, A</creator><general>PAGEPress Publications</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20090601</creationdate><title>Methylenetetrahydrofolate reductase polymorphisms in methotrexate treatment of rheumatoid arthritis patients. Review of the literature and personal experience</title><author>Taraborelli, M ; Andreoli, L ; Archetti, S ; Ferrari, M ; Cattaneo, R ; Tincani, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_24405985403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; ita</language><creationdate>2009</creationdate><topic>Rheumatoid arthritis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taraborelli, M</creatorcontrib><creatorcontrib>Andreoli, L</creatorcontrib><creatorcontrib>Archetti, S</creatorcontrib><creatorcontrib>Ferrari, M</creatorcontrib><creatorcontrib>Cattaneo, R</creatorcontrib><creatorcontrib>Tincani, A</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Reumatismo</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taraborelli, M</au><au>Andreoli, L</au><au>Archetti, S</au><au>Ferrari, M</au><au>Cattaneo, R</au><au>Tincani, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Methylenetetrahydrofolate reductase polymorphisms in methotrexate treatment of rheumatoid arthritis patients. Review of the literature and personal experience</atitle><jtitle>Reumatismo</jtitle><date>2009-06-01</date><risdate>2009</risdate><volume>61</volume><issue>2</issue><spage>98</spage><pages>98-</pages><issn>0048-7449</issn><eissn>2240-2683</eissn><abstract>Methotrexate is still a mainstay of rheumatoid arthritis treatment, but a significant variability in drug response is observed among patients. It has been proposed that C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase (MTHFR), an enzyme involved in the folate pathway, could be related to its efficacy and toxicity. Many studies have investigated the predictive value of such polymorphisms for Methotrexate outcome, though with discordant results. Our experience on 79 patients did not find any significant association between genotype and drug response and the review of the literature did not provide sufficient evidences to support the use of MTHFR genetic screening in clinical practice.</abstract><cop>Pavia</cop><pub>PAGEPress Publications</pub><doi>10.4081/reumatismo.2009.98</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0048-7449
ispartof Reumatismo, 2009-06, Vol.61 (2), p.98
issn 0048-7449
2240-2683
language eng ; ita
recordid cdi_proquest_journals_2440598540
source Publicly Available Content Database (Proquest) (PQ_SDU_P3)
subjects Rheumatoid arthritis
title Methylenetetrahydrofolate reductase polymorphisms in methotrexate treatment of rheumatoid arthritis patients. Review of the literature and personal experience
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T10%3A59%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Methylenetetrahydrofolate%20reductase%20polymorphisms%20in%20methotrexate%20treatment%20of%20rheumatoid%20arthritis%20patients.%20Review%20of%20the%20literature%20and%20personal%20experience&rft.jtitle=Reumatismo&rft.au=Taraborelli,%20M&rft.date=2009-06-01&rft.volume=61&rft.issue=2&rft.spage=98&rft.pages=98-&rft.issn=0048-7449&rft.eissn=2240-2683&rft_id=info:doi/10.4081/reumatismo.2009.98&rft_dat=%3Cproquest%3E2440598540%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_24405985403%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2440598540&rft_id=info:pmid/&rfr_iscdi=true